A team of researchers from the Netherlands Institute for Neuroscience, one of the causes is the spontaneous back-and-forth movement of the eye is pendular nystagmus. The researchers have demonstrated that the nucleus of the optic tract might be the source of the problem.
Oluwatosin U. Smith, MD, shares why she is excited for the conference and why it is relevant for today’s ophthalmologists and optometrists.
Staging AMD accurately and identifying clinical features that are linked with disease progression are key.
Theodore Leng, MD, sat down with David Hutton of Ophthalmology Times®, to discuss his ASRS presentation on how the real-world use of faricimab.
Take a look at a review of the highlights and hottest stories from Ophthalmology Times during the week of August 6, 2023.
A team of researchers at Anglia Ruskin University are harnessing nanotechnology to help tackle a common cause of sight loss.
According to Orbis International, the technology proves to be a practical solution in low-resource communities for tackling the leading cause of vision loss among working-age adults.
According to Regeneron, visual gains and safety of aflibercept 8 mg remained consistent with the established profile of aflibercept 2 mg injection.
An industrial engineer and entrepreneur, George Glady was a founder of Euclid Systems Corp. and developed the concept of the Ortho-K contact lenses.
An experienced dermatologist blinded to clinical data performed the NVC using a videocapillaroscope VideoCap 3.0 (DSMedica) at 200× magnification in the study.
According to Johns Hopkins Medicine, the gift brings T. Boone Pickens’ total donations to Wilmer to more than $28 million.
David Lally, MD, spoke with our team about the ZETA-1 phase 2 trial efficacy results for APX3330, a novel, oral ref-1 inhibitor for the treatment of diabetic retinopathy at the 2023 ASRS annual meeting.
Surgeons can refine their workflow, partner with an optometrist.
Oculis Holding AG announced, if approved, OCS-01 has the potential to become a new standard of care as the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.
Veena Raiji, MD, MPH, spoke with our team about long-term outcomes of eyes requiring IOP-lowering medication in the PALADIN trial at the 2023 ASRS annual meeting.
The US and German collaborative study found performing vitrectomy with silicone oil tamponade to manage postoperative endophthalmitis led to a significant improvement in visual acuity (VA) and had a low complication rate.
The investigators explored the effects of the following covariates on development of AMD: sex, ethnicity, smoking history, fluoxetine use, obesity, diabetes mellitus, and hypertension.
Influencers on TikTok claim the vegetable oil promotes eye health. However, ophthalmologists say the risks aren't worth any minimal benefits.
J. Fernando Arevalo, MD, PhD, FACS, FASRS, spoke with our team about clinical characteristics of macular holes that close without surgery at the 2023 ASRS annual meeting.
Canadian and Australian ophthalmologists and optometrists are looking ahead at the impact increased wildfire smoke can have on the ocular surface.
The partnership will drive Kiora's development of KIO-301, a small molecule designed to restore vision in patients with later-stage retinal degeneration.
Michael Singer, MD, spoke with our team about the Starlight Study, an optogenetic study looking at patients who had Stargardt's disease at the 2023 ASRS annual meeting. At the meeting, Nanoscope Therapeutics Inc presented key results from its STARLIGHT Phase 2 clinical trial.
The gene therapy company announces its closure less than 2 years after the company launch in 2021.
Aleksandra Rachiskaya, MD, spoke with our team about time to fluid control with faricimab arms complete compared to aflibercept at the 2023 ASRS annual meeting.
Take a look at a review of the highlights and hottest stories from Ophthalmology Times during the week of July 30, 2023.
According to the company, the therapeutic is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials.
Nancy Lurker, spoke with our team about the subgroup analyses of the Phase 1 DAVIO Trial of EYP-1901 at the 2023 ASRS annual meeting.
Paul Hahn, MD, PhD, spoke with our team about comparing the relative efficacy of pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy at the 2023 ASRS annual meeting.
.png "Optometry Times"){kind=logo}
